From: Viral hepatitis and HIV-associated tuberculosis: Risk factors and TB treatment outcomes in Thailand
Adverse events and treatment outcomes | All patients (n = 769) | Non-reactive for HBsAg and anti-HCV (n = 472) | Reactive for | Unknown (n = 17) | ||
---|---|---|---|---|---|---|
Only HBsAg (n = 43) | Only anti-HCV (n = 210) | HBsAg and anti-HCV (n = 27) | ||||
n (%) | n (%) | n (%) | n (%) | n (%) | n (%) | |
Adverse events | ||||||
Rash | 116 (15) | 69 (15) | 7 (16) | 32 (15) | 4 (15) | 4 (24) |
Immune reconstitution inflammatory syndrome* | 16 (7) | 12 (7) | 0 (0) | 2 (6) | 1 (13) | 1 (100) |
Liver disease | 41 (5) | 23 (5) | 3 (7) | 12 (6) | 2 (7) | 1 (6) |
Diarrhea | 36 (5) | 22 (5) | 2 (5) | 7 (3) | 2 (7) | 3 (18) |
Pneumonia including PCP | 30 (4) | 15 (3) | 2 (5) | 11 (5) | 1 (4) | 1 (6) |
Meningitis | 20 (3) | 11 (2) | 2 (5) | 6 (3) | 1 (4) | 0 (0) |
HIV wasting syndrome | 19 (3) | 15 (3) | 0 (0) | 1 (1) | 1 (4) | 2 (12) |
Cryptococcosis | 16 (2) | 8 (2) | 0 (0) | 8 (4) | 0 (0) | 0 (0) |
Herpes zoster | 12 (2) | 5 (1) | 2 (5) | 4 (2) | 1 (4) | 0 (0) |
Recurrent upper respiratory infections or sinusitis | 7 (1) | 5 (1) | 0 (0) | 0 (0) | 2 (7) | 0 (0) |
Treatment outcomes | ||||||
Cure | 210 (27) | 133 (28) | 7 (16) | 63 (30) | 6 (22) | 1 (6) |
Complete | 283 (37) | 190 (40) | 16 (37) | 65 (31) | 9 (33) | 3 (18) |
Failure | 6 (1) | 3 (1) | 1 (2) | 2 (1) | 0 (0) | 0 (0) |
Die | 130 (17) | 72 (15) | 5 (12) | 37 (18) | 7 (26) | 9 (53) |
Default | 65 (9) | 34 (7) | 8 (19) | 20 (10) | 1 (4) | 2 (12) |
Transfer out | 70 (9) | 37 (8) | 5 (12) | 22 (11) | 4 (15) | 2 (12) |
On treatment | 5 (1) | 3 (1) | 1 (2) | 1 (1) | 0 (0) | 0 (0) |